Lithium-Induced Idiopathic Intracranial Hypertension
Lithium monotherapy is directly associated with causing idiopathic intracranial hypertension (IIH), and no specific combination with other medications or THC is required to trigger this condition. 1
Direct Evidence from FDA Labeling
The FDA label for lithium explicitly states that cases of pseudotumor cerebri (increased intracranial pressure and papilledema) have been reported with lithium use. 1 This is a recognized adverse effect of lithium itself, not requiring combination with other agents. The label warns that if undetected, this condition may result in enlargement of the blind spot, constriction of visual fields, and eventual blindness due to optic atrophy, and recommends discontinuing lithium if clinically possible when this syndrome occurs. 1
Supporting Research Evidence
Lithium as a Causative Agent
Lithium is categorized as strongly associated with drug-induced intracranial hypertension (DIIH), classified in Categories IV and V in the most comprehensive systematic review of 259 verifiable DIIH cases spanning 1900-2019. 2 This places lithium in the highest risk category alongside vitamin A derivatives, tetracycline-class antibiotics, and recombinant growth hormone. 2
Multiple case reports document lithium-associated IIH across different age groups, including an 11-year-old boy who sustained long-term optic atrophy and vision loss requiring acetazolamide treatment for approximately 1 year after lithium cessation. 3
A 2025 case report describes a 26-year-old patient who developed pseudotumor cerebri 4 months after lithium initiation for bipolar disorder, presenting with headache and visual loss. 4
No Evidence for Combination Requirements
- The literature review of 16 lithium-associated IIH cases found no consistent pattern of combination therapy triggering the condition. 5 In most cases, the link between lithium alone and IIH remained unclear regarding whether it was coincidental or causal, but strong arguments for a causal link were found in at least two cases without mention of combination therapy. 5
THC and IIH: Therapeutic, Not Causative
- Regarding THC, the evidence suggests a therapeutic rather than causative relationship with IIH. One case report documented that dronabinol (synthetic THC) at 10 mg twice daily actually relieved symptoms of longstanding IIH, including frontal headaches, photophobia, transient blindness, enlarged blind spots, and tinnitus. 6 Previously noted papilledema and enlargement of blind spots resolved with dronabinol treatment. 6
Clinical Management Implications
When to Suspect Lithium-Induced IIH
Patients on lithium presenting with persistent headache, visual disturbances (including transient blindness, visual field constriction), pulsatile tinnitus, or papilledema should be evaluated urgently for IIH. 1, 4
The typical time course can range from weeks to months after lithium initiation, as demonstrated by the case occurring 4 months post-treatment start. 4
Decision to Discontinue Lithium
If a patient on lithium is definitively diagnosed with IIH and no other more plausible cause is identified, discontinuation of lithium is advisable. 5 However, the decision requires balancing the risk of permanent vision loss against psychiatric stability. 5
In cases where patients have clearly benefited from lithium in previous maintenance treatment, or if there is an unclear association between lithium and the onset/course of IIH, clinicians may consider restarting lithium after resolution of IIH symptoms, though this requires careful monitoring. 5
Critical Pitfall
The most dangerous pitfall is delayed recognition of lithium-induced IIH, as permanent vision loss can occur if the condition progresses undetected. 1, 3 The 11-year-old case demonstrates that even after lithium cessation, some patients sustain irreversible optic atrophy and require prolonged treatment with acetazolamide. 3